FindTrial
Sign In

To study whether FDG PET/CT scan will help in detecting the spread of cancer of the rectum.

An observational study to assess the role of FDG PET/CT in detection of systemic metastatic spread in patients of rectal cancer with lateral pelvic lymph nodes.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/12/011047
Enrollment
75
Registered
2017-12-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients who are diagnosed with rectal carcinoma

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Rectal cancer with enlarged lateral pelvic nodes. 2. Biopsy proven adenocarcinoma 3. Age > 18 years 4. Medically fit for treatment â?? surgery/ chemoradiotherapy. 5. No prior history of treatment with radiation, chemotherapy or surgery. 6. Patient willing and reliable for follow-up.

Exclusion criteria

Exclusion criteria: 1. Any other malignancy in any site. 2. Expected survival less than 6 months.

Design outcomes

Primary

MeasureTime frame
1. To evaluate the efficacy of FDG PET/CECT in detecting metastatic spread in locally advanced rectal cancer who have enlarged lateral pelvic nodes on conventional imagingTimepoint: after completion of study; i.e, after 24 months—

Secondary

MeasureTime frame
1. To evaluate the sensitivity of FDG PET/CT in detection of lateral pelvic nodes and compare with conventional imaging (CECT). 2. To follow up patients with positive lateral pelvic nodes for 3 years to look for recurrence. 3. To assess disease free and overall survival.Timepoint: 5 years—

Countries

India

Contacts

Public ContactDr Archi Agrawal

Tata Memorial Hospital

drarchi23@gmail.com9969031150

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026